Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Exelixis Inc (NQ: EXEL )

18.77 +0.11 (+0.59%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 28, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,814,164
Open 18.58
Bid (Size) 18.45 (5)
Ask (Size) 18.97 (1)
Prev. Close 18.66
Today's Range 18.51 - 18.80
52wk Range 14.87 - 23.40
Shares Outstanding 315,048,788
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Exelixis Stock Shows Rising Relative Price Performance; Still Shy Of Key Benchmark
In a welcome move, Exelixis stock saw its Relative Strength Rating improve to 73 on Monday, up from 69 a day earlier. 
Via Investor's Business Daily
Why Exelixis Stock Leaped More Than 4% Higher Today
Oh, how some investors love stock buyback programs. 
Via The Motley Fool

Performance

YTD
+15.15%
+15.15%
1 Month
+7.56%
+7.56%
3 Month
+21.25%
+21.25%
6 Month
+18.12%
+18.12%
1 Year
-13.70%
-13.70%

More News

Read More
Analyst Ratings for Exelixis
Via Benzinga
Exelixis Announces $550 Million Share Repurchase Program
From Exelixis, Inc.
Via Business Wire
3 Beaten-Down Stocks That Could Soar This Year
Via The Motley Fool
Exelixis Stock Generating Improved Relative Strength Rating
Via Investor's Business Daily
2 Stocks to Buy With Less Than $20
Via The Motley Fool
The Latest Analyst Ratings for Exelixis
Via Benzinga
Looking Into Exelixis's Return On Capital Employed
Via Benzinga
Exelixis (EXEL) Q4 2022 Earnings Call Transcript
Via The Motley Fool
The 7 Best Biotech ETFs to Buy for Exposure to the Healthcare Sector
Via InvestorPlace
Exelixis to Webcast Fireside Chat at the 2023 Guggenheim Healthy Altitudes Summit
From Exelixis, Inc.
Via Business Wire
Nasdaq Bear Market: 5 Stunning Growth Stocks You'll Regret Not Buying on the Dip
Via The Motley Fool
Benzinga's Top Ratings Upgrades, Downgrades For March 9, 2023
Via Benzinga
Roche, Exelixis Report Second Flop Out Of Three Trials Evaluating Cabozantinib/Atezolizumab Combo
Via Benzinga
US Stocks Look To Snap String Of Weekly Losses As Futures Signal Positive Start Ahead Of Service Sector Data, Fed Speeches
Via Benzinga
Dell, Zscaler, Marvell Technology And Other Big Stocks Moving Lower In Friday's Pre-Market Session
Via Benzinga
Exelixis Provides Update on Phase 3 CONTACT-03 Trial Evaluating Cabozantinib in Combination with Atezolizumab in Patients with Previously Treated Advanced Kidney Cancer
From Exelixis, Inc.
Via Business Wire
Exelixis to Webcast Fireside Chats as Part of Investor Conferences in March
From Exelixis, Inc.
Via Business Wire
Nasdaq Bear Market: 5 Magnificent Growth Stocks You'll Regret Not Buying on the Dip
Via The Motley Fool
Bristol Myers Squibb-Exelixis Highlight Three-Year Follow Up Data From Opdivo+Cabometyx Combo Therapy In Kidney Cancer
Via Benzinga
2 Under-the-Radar Biotech Stocks to Buy in 2023
Via The Motley Fool
Opdivo® (nivolumab) in Combination with CABOMETYX® (cabozantinib) Shows Durable Survival with Over Three Years of Follow-Up in the CheckMate -9ER Trial in First-Line Advanced Renal Cell Carcinoma
From Bristol Myers Squibb and Exelixis, Inc.
Via Business Wire
Exelixis and Sairopa Announce US FDA Clears Investigational New Drug Application for ADU-1805 in Patients with Advanced Solid Tumors
From Exelixis, Inc.
Via Business Wire
2 Biotech Stocks You Can Buy and Hold for the Next Decade
Via The Motley Fool
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.